Search
GS-9191
go.drugbank.com/drugs/DB15084InvestigationalGS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Categories: P-glycoprotein inhibitorsUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSomapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigationalSomapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency. This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect ...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersInterferon alfa-2c
go.drugbank.com/drugs/DB15131InvestigationalInterferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 an...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalDeutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibr...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsFutibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFutibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mast...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigationalElexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaft...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesZuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigationalZuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptors. Unlike other more common GABAA positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synap...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates